BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30026384)

  • 1. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
    Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
    Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
    Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.
    Toh CH; Wei KC; Chang CN; Ng SH; Wong HF
    AJNR Am J Neuroradiol; 2013; 34(6):1145-9. PubMed ID: 23348763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation.
    Kickingereder P; Sahm F; Wiestler B; Roethke M; Heiland S; Schlemmer HP; Wick W; von Deimling A; Bendszus M; Radbruch A
    AJNR Am J Neuroradiol; 2014 Aug; 35(8):1503-8. PubMed ID: 24722313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
    Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
    AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination between Glioblastoma and Solitary Brain Metastasis: Comparison of Inflow-Based Vascular-Space-Occupancy and Dynamic Susceptibility Contrast MR Imaging.
    Li X; Wang D; Liao S; Guo L; Xiao X; Liu X; Xu Y; Hua J; Pillai JJ; Wu Y
    AJNR Am J Neuroradiol; 2020 Apr; 41(4):583-590. PubMed ID: 32139428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
    Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
    Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
    You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
    Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
    Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma.
    Wang F; Zhou X; Chen R; Kang J; Yang X; Lin J; Liu F; Cao D; Xing Z
    Eur Radiol; 2023 Dec; 33(12):8800-8808. PubMed ID: 37439934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
    Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
    Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
    J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of brain abscesses from glioblastomas and metastatic brain tumors: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging before and after mathematic contrast leakage correction.
    Toh CH; Wei KC; Chang CN; Ng SH; Wong HF; Lin CP
    PLoS One; 2014; 9(10):e109172. PubMed ID: 25330386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric analysis from dynamic susceptibility contrast-enhanced perfusion MRI to evaluate malignant brain tumors.
    Abreu VS; Tarrio J; Silva J; Almeida F; Pinto C; Freitas D; Filipe JP
    J Neuroimaging; 2024; 34(2):257-266. PubMed ID: 38173078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.